Why Women Are Still Getting the Short End of the Stick on Weight‑Loss Drug Coverage

When I first read Carey Goldberg’s July 12 “Ideas” piece, I felt a knot tighten in my stomach – not because of the story’s subject, but because of the stark inequity it laid bare. In Massachusetts, many insurers are still playing gatekeeper with GLP‑1 drugs such as Wegovy, even though the medication has proven effective for weight loss and, for many, for controlling chronic disease.

It isn’t just a bureaucratic hiccup. Women, who statistically use these medications at higher rates, are finding themselves stuck in a loop of paperwork, appeals, and, ultimately, denials. The same insurers that readily cover hypertension or diabetes treatments often refuse to cover a drug that can, frankly, be a lifeline for obesity‑related conditions.

Look, I’m not a lawyer, and I don’t have a spreadsheet of every plan’s formulary in front of me. But the pattern is hard to ignore. A friend of mine in Boston, a 42‑year‑old mother of two, was told her plan would only cover Wegovy if she first tried a diet that, frankly, she had already tried – and failed – multiple times. When she appealed, the insurer said the drug was “experimental” for her case, despite FDA approval and mounting clinical evidence.

It feels like a double standard that women, who already face systemic hurdles in health care, are forced to jump through extra hoops to get a prescription that could change their lives. If a man with type 2 diabetes can get his medication without a saga, why should a woman battling obesity be treated differently?

In a perfect world, coverage decisions would rest on solid science, not on outdated notions of who “needs” a drug. The reality, however, is that insurance policies often lag behind the latest research, and the lag disproportionately hurts women.

We need a conversation – a genuine one – between policymakers, insurers, and the patients whose lives hang in the balance. Until we get there, many women will continue to stare at the same insurance denial letters, wondering whether the system will ever see weight loss as a legitimate medical necessity rather than a lifestyle choice.

To the Massachusetts Department of Insurance and every health‑plan executive reading this: please re‑examine your coverage criteria for GLP‑1 drugs. The data are clear, the need is real, and the cost of inaction is measured in the health and wellbeing of countless women across our Commonwealth.